Skip to content

Amgen

NASDAQ: AMGN · USD

Amgen revenue97

Quarterly and annual revenue from company filings.

Business drivers

Business lines and operating measures.

Repatha revenue

Reported quarterly Repatha revenue. Quarterly figures · USD

Repatha revenue. Reported quarterly Repatha revenue. Unit: USD. All reporting dates and source links follow.
Period endedUSDReport
Jun 30, 2026From Apr 1, 2026953,000,000Filed Aug 5, 2026
Mar 31, 2026From Jan 1, 2026876,000,000Filed May 1, 2026
Jun 30, 2025From Apr 1, 2025696,000,000Filed Aug 5, 2026
Mar 31, 2025From Jan 1, 2025656,000,000Filed May 1, 2026

Prolia revenue

Reported quarterly Prolia revenue. Quarterly figures · USD

Prolia revenue. Reported quarterly Prolia revenue. Unit: USD. All reporting dates and source links follow.
Period endedUSDReport
Jun 30, 2026From Apr 1, 2026759,000,000Filed Aug 5, 2026
Mar 31, 2026From Jan 1, 2026727,000,000Filed May 1, 2026
Jun 30, 2025From Apr 1, 20251,122,000,000Filed Aug 5, 2026
Mar 31, 2025From Jan 1, 20251,099,000,000Filed May 1, 2026

TEPEZZA revenue

Reported quarterly TEPEZZA revenue. Quarterly figures · USD

TEPEZZA revenue. Reported quarterly TEPEZZA revenue. Unit: USD. All reporting dates and source links follow.
Period endedUSDReport
Jun 30, 2026From Apr 1, 2026576,000,000Filed Aug 5, 2026
Mar 31, 2026From Jan 1, 2026490,000,000Filed May 1, 2026
Jun 30, 2025From Apr 1, 2025505,000,000Filed Aug 5, 2026
Mar 31, 2025From Jan 1, 2025381,000,000Filed May 1, 2026

Independent series; they may overlap and do not form an additive breakdown.

  • The supplied quarterly histories are discontinuous.
  • Product sales do not distinguish volume changes from pricing or mix effects.

Products & projects

Repatha

In November 2025, we announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha achieved statistically significant and clinically meaningful reductions in MACEs in high-risk adults without a prior heart attack or stroke, when added to statins or other LDL-C–lowering treatments.

Filed · source for Repatha

clinical manufacturing network

We also use third-party contract manufacturers, including contract manufacturers that were added to our clinical manufacturing network from the Horizon acquisition, to supplement the capacity or capability of our overall clinical manufacturing network.

Filed · source for clinical manufacturing network

Revenue history

USD millions · Fiscal periods
Jun 30, 2009 through Jun 30, 2026

Quarterly data

Amgen quarterly financial data in USD millions. FY denotes the company's fiscal year. YTD covers reported quarters only.
Fiscal quarterEndedTotal revenueUSD millions
FY 2026 Q2Jun 30, 202610,054, +16.7% versus FY 2026 Q1
FY 2026 Q1Mar 31, 20268,618, −12.6% versus FY 2025 Q4
FY 2025 Q4Dec 31, 20259,866, +3.2% versus FY 2025 Q3
FY 2025 Q3Sep 30, 20259,557, +4.1% versus FY 2025 Q2
FY 2025 Q2Jun 30, 20259,179, +12.6% versus FY 2025 Q1
FY 2025 Q1Mar 31, 20258,149, −10.3% versus FY 2024 Q4
FY 2024 Q4Dec 31, 20249,086, +6.9% versus FY 2024 Q3
FY 2024 Q3Sep 30, 20248,503, +1.4% versus FY 2024 Q2
FY 2024 Q2Jun 30, 20248,388, +12.6% versus FY 2024 Q1
FY 2024 Q1Mar 31, 20247,447, −9.1% versus FY 2023 Q4
FY 2023 Q4Dec 31, 20238,196, +18.7% versus FY 2023 Q3
FY 2023 Q3Sep 30, 20236,903, −1.2% versus FY 2023 Q2
FY 2023 Q2Jun 30, 20236,986, +14.4% versus FY 2023 Q1
FY 2023 Q1Mar 31, 20236,105, −10.7% versus FY 2022 Q4
FY 2022 Q4Dec 31, 20226,839, +2.8% versus FY 2022 Q3
FY 2022 Q3Sep 30, 20226,652, +0.9% versus FY 2022 Q2
FY 2022 Q2Jun 30, 20226,594, +5.7% versus FY 2022 Q1
FY 2022 Q1Mar 31, 20226,238, −8.9% versus FY 2021 Q4
FY 2021 Q4Dec 31, 20216,846, +2.1% versus FY 2021 Q3
FY 2021 Q3Sep 30, 20216,706, +2.8% versus FY 2021 Q2
FY 2021 Q2Jun 30, 20216,526, +10.6% versus FY 2021 Q1
FY 2021 Q1Mar 31, 20215,901, −11.0% versus FY 2020 Q4
FY 2020 Q4Dec 31, 20206,634, +3.3% versus FY 2020 Q3
FY 2020 Q3Sep 30, 20206,423, +3.5% versus FY 2020 Q2
FY 2020 Q2Jun 30, 20206,206, +0.7% versus FY 2020 Q1
FY 2020 Q1Mar 31, 20206,161, −0.6% versus FY 2019 Q4
FY 2019 Q4Dec 31, 20196,197, +8.0% versus FY 2019 Q3
FY 2019 Q3Sep 30, 20195,737, −2.3% versus FY 2019 Q2
FY 2019 Q2Jun 30, 20195,871, +5.7% versus FY 2019 Q1
FY 2019 Q1Mar 31, 20195,557, −10.8% versus FY 2018 Q4
FY 2018 Q4Dec 31, 20186,230, +5.5% versus FY 2018 Q3
FY 2018 Q3Sep 30, 20185,904, −2.6% versus FY 2018 Q2
FY 2018 Q2Jun 30, 20186,059, +9.1% versus FY 2018 Q1
FY 2018 Q1Mar 31, 20185,554, −4.3% versus FY 2017 Q4
FY 2017 Q4Dec 31, 20175,802, +0.5% versus FY 2017 Q3
FY 2017 Q3Sep 30, 20175,773, −0.6% versus FY 2017 Q2
FY 2017 Q2Jun 30, 20175,810, +6.3% versus FY 2017 Q1
FY 2017 Q1Mar 31, 20175,464, −8.4% versus FY 2016 Q4
FY 2016 Q4Dec 31, 20165,965, +2.7% versus FY 2016 Q3
FY 2016 Q3Sep 30, 20165,811, +2.2% versus FY 2016 Q2
FY 2016 Q2Jun 30, 20165,688, +2.9% versus FY 2016 Q1
FY 2016 Q1Mar 31, 20165,527, −0.2% versus FY 2015 Q4
FY 2015 Q4Dec 31, 20155,536, −3.3% versus FY 2015 Q3
FY 2015 Q3Sep 30, 20155,723, +6.6% versus FY 2015 Q2
FY 2015 Q2Jun 30, 20155,370, +6.7% versus FY 2015 Q1
FY 2015 Q1Mar 31, 20155,033, −5.6% versus FY 2014 Q4
FY 2014 Q4Dec 31, 20145,331, +6.0% versus FY 2014 Q3
FY 2014 Q3Sep 30, 20145,031, −2.9% versus FY 2014 Q2
FY 2014 Q2Jun 30, 20145,180, +14.6% versus FY 2014 Q1
FY 2014 Q1Mar 31, 20144,521, −9.8% versus FY 2013 Q4
FY 2013 Q4Dec 31, 20135,011, +5.5% versus FY 2013 Q3
FY 2013 Q3Sep 30, 20134,748, +1.5% versus FY 2013 Q2
FY 2013 Q2Jun 30, 20134,679, +10.4% versus FY 2013 Q1
FY 2013 Q1Mar 31, 20134,238, −4.1% versus FY 2012 Q4
FY 2012 Q4Dec 31, 20124,421, +2.4% versus FY 2012 Q3
FY 2012 Q3Sep 30, 20124,319, −3.5% versus FY 2012 Q2
FY 2012 Q2Jun 30, 20124,477, +10.6% versus FY 2012 Q1
FY 2012 Q1Mar 31, 20124,048, +1.9% versus FY 2011 Q4
FY 2011 Q4Dec 31, 20113,973, +0.7% versus FY 2011 Q3
FY 2011 Q3Sep 30, 20113,944, −0.4% versus FY 2011 Q2
FY 2011 Q2Jun 30, 20113,959, +6.8% versus FY 2011 Q1
FY 2011 Q1Mar 31, 20113,706, −3.5% versus FY 2010 Q4
FY 2010 Q4Dec 31, 20103,841, +0.7% versus FY 2010 Q3
FY 2010 Q3Sep 30, 20103,816, +0.3% versus FY 2010 Q2
FY 2010 Q2Jun 30, 20103,804, +5.9% versus FY 2010 Q1
FY 2010 Q1Mar 31, 20103,592, −5.7% versus FY 2009 Q4
FY 2009 Q4Dec 31, 20093,809, −0.1% versus FY 2009 Q3
FY 2009 Q3Sep 30, 20093,812, +2.7% versus FY 2009 Q2
FY 2009 Q2Jun 30, 20093,713, Change unavailable versus FY 2009 Q1
Sources and definitions

Figures from official company filings and financial reports, in the reported currency. FY identifies the fiscal year; the end date identifies the calendar period. Last checked Oct 19, 2026.

Annual values come from annual filings. Historical quarters retain their reporting basis; rounding and reclassifications can make their sum differ from the annual figure. YTD sums the available fiscal quarters and compares the same quarters of the previous fiscal year.

Missing values are shown as unavailable. Fourth quarters use reported values where available, otherwise the annual amount less the matching nine-month amount.

Total revenue
Reported consolidated revenue from the issuer filing. Each observation identifies its accounting concept; bank net revenue is net of interest expense when that concept is reported.